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Introduction. Impaired maternal immune tolerance resulting in systemic inﬂammation plays a pivotal role in the pathogenesis of
preeclampsia. Phenotypical changes of monocytes and neutrophil granulocytes have already been studied in preeclampsia, and
some studies also included T lymphocyte activation markers; however, the results are controversial and a comprehensive
analysis of activation markers is lacking. The characteristics of cellular adhesion molecules in preeclampsia are yet to be
described. Material and Methods. Peripheral blood samples of 18 preeclamptic patients and 20 healthy pregnant women in the
third trimester were evaluated using ﬂow cytometry to characterize the cell surface expression of T lymphocyte activation
markers and selectins. Results. We found an elevated ratio of HLA-DR and CD122-, CD62E-, and CD62L-expressing cells
among the CD4+ T lymphocytes in PE in comparison to healthy pregnancy. No alterations were found in the prevalence of
CD69-, CD25-, and CD62P-expressing lymphocytes and CD11c-expressing monocytes. Conclusions. Our ﬁndings support the
role of activated T lymphocytes and speciﬁc cell adhesion molecules in the pathogenesis of preeclampsia.
1. Introduction
Of the many challenges that the immune system must
face, the one presented by pregnancy is among the most
complex and critically important ones. The development
of speciﬁc immunotolerance towards the semiallogeneic
fetal antigens is the most essential requirement for a suc-
cessful pregnancy. The impairment of the maternal-fetal
tolerance is the cornerstone of many pregnancy-speciﬁc
diseases of which preeclampsia is linked to the highest
degrees ofmaternal and fetalmorbidity andmortality indevel-
oped countries. Preeclampsia (PE) occurs in approximately
5% of all pregnancies but is responsible for approximately
15% of all maternal mortality and 20% of premature
births. The only causal therapy is acute iatrogenic deliv-
ery, which can lead to further perinatal complications.
While several aspects of the pathogenesis are poorly under-
stood, most ﬁndings support the central role of immune
maladaptation-driven superﬁcial placentation, leading to a
systemic maternal inﬂammatory response, in which the role
of activated T lymphocytes appears to be pivotal [1–3].
Monitoring the activation-induced responses of T lym-
phocytes could help gain a better understanding of the
underlying pathophysiological processes.
Upon T cell activation, several cell surface markers
are upregulated, each at a diﬀerent stage of the activation
process. The earliest activation marker is CD69, which is
an inducible cell surface glycoprotein expressed upon activa-
tion via the TCR or the IL-2 receptor (CD25). It plays a
role in the proliferation and survival of activated T lym-
phocytes [4, 5]. It is expressed at very low basal levels in
resting lymphocytes; however, upon activation with phytohe-
magglutinin (a mitogen causing activation via the TCR) its
expression increases in a time-dependent manner between
3 and 12 hours, remaining elevated until 24 hours and
declining thereafter [6].
IL-2 plays a key role in the activation, survival, expansion,
and function of T lymphocytes. It also appears to be crucial in
the maintenance of regulatory T cell- (Treg-) mediated
immunotolerance toward self-antigens, supported by the fact
that IL-2-deﬁcient mice develop severe autoimmunity with
very low Treg and very high eﬀector T numbers [7–9].
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CD25 is the alpha chain of the trimeric IL-2 receptor and
considered to be the most prominent cellular activation
marker. It is expressed constitutively on the surface of
several subsets of peripheral blood lymphocytes, such as
regulatory and resting memory T cells. It is upregulated
within 24 hours of stimulation of the TCR/CD3 complex
and remains elevated for a few days [6, 10]. It plays a key role
in responsiveness to IL-2 resulting in lymphocyte activation
and further IL-2 production. Several cytokines released by
monocytes and macrophages as well as other agents trigger-
ing T cell activation (such as oxidized LDL) are capable of
inducing CD25 expression [11, 12]. CD122 is the β-chain
of the IL-2 receptor, and upon expression, it further
increases sensitivity of activated CD25+ T lymphocytes
to IL-2. Together with the common γ-chain and CD25, it
forms the high-aﬃnity trimeric IL-2 receptor [13].
HLA-DR is a human class II major histocompatibility
complex (MHC) antigen which is constitutively expressed
on the surface of B lymphocytes, monocytes, and macro-
phages and appears at the late stages of activation on T and
NK cells; thus, it is considered to be a very late activation
marker [14].
Reddy et al. demonstrated that resting peripheral blood
lymphocytes of healthy individuals show little or no expres-
sion of CD69 (very early) and moderate basal expression
of CD25 (late) and HLA-DR (very late) markers. They
demonstrated that the peak elevation of CD69 precedes
the appearance of CD25 and HLA-DR, which showed pro-
gressive increase in expression after 24 hours [6].
Although the role of activated T lymphocytes is clear
in the pathogenesis of preeclampsia, previous studies have
been unable to detect alterations in the ratio of CD3/CD69
cells and the rate of CD25-expressing lymphocytes in pre-
eclampsia in comparison with healthy pregnancy [2, 15].
Cell adhesion molecules are membrane proteins that
regulate the adhesion of activated T cells to activated
endothelial cells, thus are thought to play an important
role in the regulation of inﬂammatory processes [16–18].
Selectins are a subset of cell adhesion molecules, which
mediate the ﬁrst step of adhesion (rolling) by decreasing
leukocyte velocity upon endothelial contact [19, 20], which
is followed by leukocyte arrest and endothelial transmigra-
tion. Naive T cells use CD62L (L-selectin) among other
receptors to recognize and extravasate through specialized
high endothelial venules of lymphoid tissue but lack the
receptors to exit via other blood vessel types [21, 22].
The majority of activated T cells rapidly shed CD62L
receptors and gain a new set of selectins which allow them
to migrate to nonlymphoid tissues. Activated T cells are
known to enter the skin via inﬂamed blood vessels, by
binding via selectin ligands to CD62P (P-selectin) and
CD62E (E-selectin) expressed by endothelial cells [23].
Until recently, studies have failed to detect the expression
of E selectin on activated lymphocytes; thus, they were
thought to be solely expressed by endothelial cells. However,
Vainer et al. were able to demonstrate that in ulcerative
colitis, mononuclear cells of the lamina propria are also
E-selectin positive, indicating the altered role of this selectin
in an ongoing inﬂammation [24].
β2 integrins (CD11a, CD11b, and CD11c) expressed
by neutrophils and monocytes establish a ﬁrm leukocyte-
endothelial adhesion by reducing rolling velocity of
activated monocytes.
The aim of the present study was to gain a comprehensive
understanding of the alterations of T lymphocyte activation
markers and selectins in preeclampsia. We aimed to charac-
terize the cell surface expression of lymphocyte activation
markers CD69, HLA-DR, CD25, and CD122 and the
expression of the selectins playing a role in the adhesion and
extravasation of activated T lymphocytes CD62E, CD62L,
and CD62P.We also aimed to characterize the CD11c expres-
sion of monocytes to monitor their activation rate.
2. Material and Methods
2.1. Sample Collection.We collected peripheral venous blood
samples from 18 preeclamptic pregnant women on average at
the 36th week of pregnancy. PE was diagnosed according to
the standard, internationally accepted criteria, which include
hypertension (deﬁned as systolic blood pressure and/or
diastolic blood pressure≥ 140mmHg and ≥90mmHg, resp.)
occurring after 20 weeks of gestation and proteinuria
(deﬁned as presence of ≥0.3 g protein in a 24-hour urine
specimen). 20 healthy pregnant (HP) women were enrolled
as controls on average at the 36th gestational age. Clinical
characteristics of participants are summarized in Table 1.
PE was regarded as severe if any of the following cri-
teria was present: blood pressure≥ 160mmHg systolic or
≥110mmHg diastolic or proteinuria ≥5 g/24 h (or 3+ on
dipstick). Early onset of PE was deﬁned as onset of the
disease before 34 weeks of gestation. Our study was reviewed
and approved by an independent ethical committee of the
institution (Scientiﬁc and Research Ethics Committee,
Semmelweis University, Budapest, Hungary; date of issue
and registration number: 2008.04.08/ TUKEB 56/2008), and
written informed consent was obtained from all participants.
The study was adhered to the tenets of the most recent
revision of the Declaration of Helsinki.
2.2 Flow Cytometry. 9ml of peripheral venous blood was col-
lected from each woman in lithium heparin-treated tubes
(BD Vacutainer, BD Biosciences, San Jose, CA). Peripheral
blood mononuclear cells (PBMCs) were isolated by standard
density gradient centrifugation (Ficoll Paque, AmershamBio-
sciences AB, Uppsala, Sweden; 25min, 400 g, room tempera-
ture). Cells were kept at −80°C in Fetal Bovine Serum
containing 10% DMSO until analysis. After thawing, cells
were washed twice in phosphate-buﬀered saline.
PBMCs were incubated for 30min at room temperature in
the dark with the following antibodies: APC-Cy7-conjugated
CD4, PerCP-conjugated HLA-DR, APC-conjugated CD62E,
PE-Cy7-conjugated CD62L, PE-conjugated CD62P, FITC-
conjugated CD25, PE-Cy7-conjugated CD11c, PE-conjugated
CD122, and APC-conjugated CD69 (BD Biosciences).
After washing, ﬂuorescent data were registered on a BD
FACSAria ﬂow cytometer (BD Biosciences). Data were
processed using the FACSDiVa software. 200000 cells
per sample were recorded.
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2.3. Statistics. Data are expressed as median and interquartile
range (IQR). Comparisons between the two patient groups
were made with the Mann–Whitney U test, as a test of
normality (according to Kolmogorov-Smirnoﬀ) indicated
nonnormal distribution of data. p values less than 0.05 were
considered signiﬁcant. Sample size was estimated to achieve
80% power with 0.6 eﬀect size to detect diﬀerences between
the two study populations. Statistics were calculated using
the GraphPad software (Prism version 5.00 for Windows,
GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Activation Markers. Our results are summarized in
Figure 1 and Table 2. Within CD4+ T lymphocytes, we found
no alterations in the prevalence of CD69-expressing T cells
(very early activation marker) and CD25-expressing T cells
(late activation marker). However, the prevalence of CD4+
HLA-DR+ T lymphocytes was signiﬁcantly higher in women
with PE, than in HP women (6.19% (3.02–13.73) versus
21.05% (9.98–46.03), p = 0 0075).
In PE, within the CD4+ T cells, the percentage of
activated CD122+ lymphocytes was also higher (1.20%
(0.67–1.81) versus 1.63% (1.20–2.28), p = 0 0437). We found
no alterations in the prevalence of CD11c+ monocytes in PE.
3.2. Selectins. We found an elevated prevalence of CD4+
CD62L+ lymphocytes in PE (1.74% (1.03–3.64) versus
2.91% (2.49–4.30), p = 0 0124). We found that CD4+ lym-
phocytes isolated from both groups expressed CD62E, with
a distinct elevation in the prevalence of CD4+ CD62E+ lym-
phocytes in women with PE compared to HP women (5.77%
(2.26–10.96) versus 16.10% (8.25–38.80), p = 0 0141). The
prevalence of CD62P+ lymphocytes in the CD4+ T cell
population did not diﬀer between the two groups.
CD4+ CD62L+ CD4+ HLA‒DR+ CD4+ CD25+ CD4+ CD69+
CD4+ CD62E+ CD4+ CD62P+ CD4+ CD122+ CD11c+
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Figure 1: Box plots representing the frequency of the investigated cell subsets in healthy pregnancy (control) and preeclampsia (PE).
Horizontal line: median; box: interquartile range (25–75 percentile); whisker: range. ∗p < 0 05 versus control.
Table 1: Clinical characteristics of study participants.
Healthy pregnant women (n = 20) Preeclamptic women (n = 18)
Maternal age (years) 33.5 (30–35.25) 32.5 (26.5–34.75)
BMI 26.5 (23.4–28.3) 30 (28–33.4)
Systolic blood pressure (mmHg) 110 (104.75–116.25) 140∗ (138–155)
Diastolic blood pressure (mmHg) 67.5 (60–70) 90∗ (90–100)
Proteinuria (g/24 h) (cross) — 0.91 (0.65–2.035) (+++)
Gestational age at diagnosis (week) — 36 (28–38)
Gestational age at blood sample collection (week) 36 (34–37) 36 (29.25–38)
Fetal birth weight (g) 3180 (2985–3632.5) 2560∗ (1295–3450)
Early onset preeclampsia — 7 (39%)
Severe preeclampsia — 12 (67%)
Data are presented as median (interquartile range) for continuous variables and as number (percentage) for categorical variables. ∗p < 0 05 versus healthy
pregnant women.
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4. Discussion
In this study, we analyzed the expression of activation
markers and selectins on the surface of peripheral T lym-
phocytes and monocytes in preeclampsia compared to
healthy pregnancy.
The role of activated T lymphocytes in the pathogenesis
of PE is supported by several studies [25, 26]. Some also
described activation markers; however, the results are
controversial and a comprehensive analysis of activation
markers is lacking. While some studies observed elevated
levels of CD25+ T lymphocytes [27], others reported
decreased percentage of CD3+ cells and CD25+ T lympho-
cytes with increased prevalence of CD4+ HLA-DR+ T
lymphocytes in PE compared with HP [28]. Therefore, we
aimed to complete a comprehensive analysis of the most
important T lymphocyte activation markers.
Wilczyński et al. isolated lymphocytes from the third
trimester decidua of preeclamptic pregnant patients and
healthy pregnant controls and investigated the expression
of certain cell surface receptors, including CD69; however,
they found no alterations in the CD3/CD69 decidual
lymphocyte subset in preeclampsia compared to healthy
pregnancy [15]. Rieger et al. investigated the changes of
decidual leukocyte populations in preeclampsia; however,
they were unable to detect any alterations in the rate of
CD25-expressing cells in preeclampsia compared to healthy
pregnancy [2]. Our results are in line with these previous
ﬁndings, since we found no diﬀerence between preeclamptic
and healthy pregnant women in the expression rate of very
early activation marker CD69 and late activation marker
CD25. However, we found a signiﬁcant elevation in the
rate of HLA-DR-expressing cells among the CD4+ T lym-
phocytes in PE compared to HP. HLA-DR is the very late
activation marker of T lymphocytes, the expression of which
starts elevating after 24 hours following a stimulus and
remains high for up to a few weeks. Preeclampsia is a chronic,
often slowly developing, progressive disease, which results in
a chronic inﬂammatory status accompanied by increased
antigen presentation. Therefore, it is tempting to hypothesize
that since at the time of sampling, there has been an ongoing
inﬂammation for up to a few weeks; the very early (CD69)
and even the late (CD25) activation markers are no longer
signiﬁcantly elevated on the surface of T lymphocytes.
However, it appears that the very late activation marker
(HLA-DR) closely mirrors the chronic T cell activation
present in PE. Results from previous studies are somewhat
incongruent, since some found no alterations in the preva-
lence of CD4+ CD25+ lymphocytes [29], while others found
an elevated level of CD25 expression among CD4+ lym-
phocytes [25, 27]. Similarly, some studies reported no
alterations in the expression of HLA-DR among CD4+
lymphocytes [25], while others found an elevated ratio of
CD4+ HLA-DR+ lymphocytes [28]. It is important to note
that it is almost impossible to predict the time which has
passed from the development of PE until the time of clinical
admission; thus, it is highly challenging to standardize the
time of sample collection. Since, at diﬀerent points of lym-
phocyte activation process, diﬀerent activation markers are
upregulated, it is entirely possible that the diﬀerences in the
time passed between the onset of PE and the sample collec-
tion could account for the abovementioned incongruity,
especially since we also observed an elevating tendency in
the expression of CD25 in CD4+ lymphocytes, which did
not reach a signiﬁcant level.
Loewendorf et al. investigated the ratio of T cells at the
uteroplacental interface (UPI) and in the peripheral blood
in healthy pregnancy and found that the distribution of
CD4 and CD8 T cell populations in the peripheral blood
largely mirror that in the UPI. They applied a simple staining
and gating strategy developed by Sakaguchi [30] that
allows for the analysis of three regulatory T cell (Treg)
subtypes with the following distinct biological features:
resting Tregs (FoxP3 low, CD45RA+), cytokine Tregs (FoxP3
low,CD45RA-), and activatedTregs (FoxP3high,CD45RA+).
The HLA-DR expression of the three Treg subsets was
described, since HLA-DR expression identiﬁes a highly sup-
pressive Treg population. They found that while resting Treg
cells express low levels of HLA-DR, there is a focal enrich-
ment of HLA-DR-expressing cytokine Tregs. This increase
in HLA-DR+ cytokine Tregs at the UPI mirrored the increase
of the HLA-DR+ CD8 T cell subset, resulting in a similar
ratio of responder CD8 T cells and suppressor regulatory T
cells at the UPI and at the periphery. They hypothesized that
Table 2: Prevalence of the investigated cell subsets.
Healthy pregnancy (n = 20) Preeclampsia (n = 18) p value
Activation markers
CD4+ CD69+/CD4+ 2.28 (1.77–3.27) 2.61 (1.68–2.97) 0.8151
CD4+ CD25+/CD4+ 7.38 (5.39–9.64) 9.51 (5.03–12.70) 0.5686
CD4+ HLA-DR+/CD4+ 6.19 (3.02–13.73) 21.05∗ (9.98–46.03) 0.0075
CD4+ CD122+/CD4+ 1.20 (0.67–1.81) 1.63∗ (1.20–2.28) 0.0437
CD11c+/monocytes 2.57 (1.94–3.83) 2.43 (1.39–4.39) 0.5827
Selectins
CD4+ CD62E+/CD4+ 5.77 (2.26–10.96) 16.10∗ (8.25–38.80) 0.0141
CD4+ CD62L+/CD4+ 1.74 (1.03–3.64) 2.91∗ (2.49–4.30) 0.0124
CD4+ CD62P+/CD4+ 9.53 (5.04–19.05) 10.70 (8.54–13.20) 0.6068
Data are presented as median (interquartile range). ∗p < 0 05 versus healthy pregnant women.
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the alterations of the ratio of HLA-DR-expressing T cell
subsets might be important in pathological conditions, such
as preeclampsia [1].
CD122, which is the β-chain of the IL-2 receptor, is an
important T cell activation antigen; however, it has not
been previously investigated in preeclampsia. We found an
elevated rate of CD122-expressing cells among the CD4+ T
lymphocyte population in PE compared with HP. As a com-
ponent of the high-aﬃnity trimeric IL-2 receptor, CD122
plays a key role in increasing the sensitivity to IL-2, thus
regulating T lymphocyte survival, expansion, and activation.
The elevated expression of this cell surface antigen indicates
an increased activation rate among the CD4+ lymphocytes.
These ﬁndings further support the role of activated T
lymphocytes in the development of PE.
CD62E, CD62L, and CD62P play a central role in the
adhesion of activated T lymphocytes to activated endothelial
cells. Rolling enables leukocytes to sense proinﬂammatory
cytokines and chemokines produced by activated endothelial
cells at the site of inﬂammation [31, 32], and thus selectins
also regulate the homing of activated T lymphocytes to the
site of inﬂammation. Therefore, lymphocytes are able to
exit to lymphoid tissue for maturation (via CD62L) and
to the site of inﬂammation in nonlymphoid tissues (con-
nections via CD62E and CD62P). Until recently, CD62E
was believed to be expressed solely by endothelial cells;
however, Vainer et al. demonstrated that in colonic biop-
sies obtained from ulcerative colitis patients in the active
stage of the disease, E-selectin is expressed not only by
epithelial and endothelial cells of the luminal membrane
but also by mononuclear cells [24]. E-selectin expression
is also modiﬁed by a number of cytokines. Proinﬂammatory
cytokines, such as TNF-α and IL-1, upregulate the transcrip-
tion of CD62E, while TGF-β downregulates the transcription
of CD62E [33, 34]. Harashima et al. demonstrated that
E-selectin expression can be induced not only on endo-
thelial cells but also on CD41+ T cells and on Jurkat cells
by TNF-α [35]. It is likely that in certain inﬂammatory
conditions, in order to enhance the adhesion process, E-
selectin expression is not limited to endothelial cells but is
also expressed by mononuclear cells. Our results support this
hypothesis, since we found a threefold elevation in the rate of
CD62E-expressing CD4+ T lymphocytes in PE compared
with HP. It is important to note that CD4+ T lymphocytes
also expressed CD62E in HP women, suggesting that
pregnancy alone could alter the expression of this selectin.
However, the signiﬁcant elevation found in PE indicates that
it could play an important role in the increased extravasation
of activated T lymphocytes in preeclampsia.
We also found an elevated rate of CD62L-expressing cells
among CD4+ T lymphocytes, which indicates an increased
tendency of naive T lymphocytes to exit to lymphoid tissue,
where they meet speciﬁc antigens and undergo maturation
and activation process and rapidly shed CD62L thereafter.
CD62L is also considered a late T lymphocyte activation
marker, since naive T lymphocytes are characterized by
high expression of CD62L (CD62hi), whereas activated T
lymphocytes can be characterized by low expressions of
CD62L (CD62lo), and the rate of CD62L shedding can
be utilized to describe leukocyte activation rate [36]. The
prevalence of CD62P+ T lymphocytes did not diﬀer
between the two study groups; therefore, we hypothesize
that the role of this selectin is secondary in the pathophys-
iology of PE.
Activated monocytes play a role in antigen presentation
and the activation process of T lymphocytes. An elevated
rate of monocyte activation could indicate the presence
of increased antigen presentation. β2 integrins (CD11a,
CD11b, and CD11c) play a role in the adhesion of activated
monocytes to activated endothelial cells. Mellembakken
et al. reported an elevated expression of CD11a and CD11c
integrins on the surface of monocytes isolated from uterine
venous blood samples compared with those isolated from
antecubital venous samples in preeclampsia. They found
an elevated expression of integrins on neutrophils and
monocytes isolated from uterovenous samples in preeclamp-
sia when compared with uncomplicated pregnancy. They
hypothesized that there is an increased rate of monocyte
activation taking place at the uteroplacental passage leading
to enhanced leukocyte-endothelial interactions in pre-
eclampsia, resulting in increased neutrophil inﬁltration and
elevated presence of mononuclear perivascular cells in the
decidua. They suggested that therapeutic blocking of
integrin-mediated leukocyte-endothelial interaction might
be beneﬁcial [37]. We found no alteration in the rate of
CD11c-expressing peripheral monocytes. A possible expla-
nation is the aforementioned diﬀerence in the prevalence of
integrin-expressing monocytes between uterovenous and
antecubital venous samples, indicating the accumulation of
activated monocytes at the UPI.
5. Conclusion
In summary, our current ﬁndings are in line with previous
ﬁndings and suggest that activated T lymphocytes play an
important role in the pathogenesis of PE [38]. While the very
early (CD69) and late (CD25) T lymphocyte activation
markers were no longer elevated, HLA-DR, the very late
activation marker, and CD122, a pivotal regulator of T cell
activation and survival, was signiﬁcantly higher in pre-
eclampsia than in healthy pregnancy, mirroring the chronic
inﬂammatory process. From the cell adhesion molecules,
CD62E, which is presumably only expressed by lymphocytes
in inﬂammatory conditions, was signiﬁcantly upregulated in
PE compared to HP. However, it also appeared in the surface
of lymphocytes isolated from healthy pregnant controls,
indicating that pregnancy alone could be an altering factor
in the expression of this selectin. The elevated expression of
CD62L suggests the increased maturation and activation of
naive T cell subsets. These cell adhesion molecules could play
a role in the inﬂammatory site-speciﬁc extravasation of
lymphocytes in PE.
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